Previous 10 | Next 10 |
Roivant Sciences Ltd. (ROIV) Q4 2021 Results Earnings Conference Call June 28, 2022, 08:00 AM ET Company Participants Paul Davis - Head, Communications Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Frank Torti - Vant Chair Eric Venker - President and Chief Opera...
The following slide deck was published by Roivant Sciences Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Roivant Sciences Ltd. 2022 Q1 - Results - Earnings Call Presentation
Roivant Sciences (NASDAQ:ROIV) is ending development of its top lentiviral gene therapy, ARU0-1801, for sickle cell disease and β-thalassemia, due to future development costs and current market environment. Also, as part of a pipeline review, the company is abandoning DMVT-502 for...
U.K.-based pharmaceutical company Roivant Sciences (NASDAQ:ROIV) and Pfizer (PFE) announced on Tuesday the launch of Priovant Therapeutics, a clinical-stage biotech focused on autoimmune diseases. In September 2021, Pfizer (PFE) licensed global development rights and certain commercial rights...
Roivant Sciences press release (NASDAQ:ROIV): Q4 GAAP EPS of -$0.39 misses by $0.09. Revenue of $9.22M (-39.1% Y/Y) misses by $2.35M. Shares +2.35% AH. For further details see: Roivant Sciences GAAP EPS of -$0.39 misses by $0.09, revenue of $9.22M misses by $2.35M
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support prog...
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is developing brepocitinib in severe autoim...
Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
Better Therapeutics (BTTX) +12%. Insulet Corporation (PODD) +11% DexCom - Insulet buyout deal unlikely, Bank of America says. Cango (CANG) +10%. Roivant Sciences (ROIV) +10% gets FDA approval for plaque psoriasis therapy Vtama cream. Creative Medical Technology (CELZ) +9%....
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...